menu
    • menu
    [{"orgOrder":0,"company":"Alzheimers Drug Discovery Foundation","sponsor":"Astrocyte Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"||Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzheimers Drug Discovery Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Alzheimers Drug Discovery Foundation","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"COYA 302","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Alzheimers Drug Discovery Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Alzheimers Drug Discovery Foundation","sponsor":"CuraSen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"CST-3056","moa":"||Adrenergic-alpha-1A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzheimers Drug Discovery Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Alzheimers Drug Discovery Foundation \/ Alzheimers Drug Discovery Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Alzheimers Drug Discovery Foundation

    Menu

    Alzheimers Drug Discovery Foundation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COYA 302,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Coya Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Coya Therapeutics Announces $5 Million Investment by Alzheimer’s Drug Discovery Foundation

                            Details : The financing will accelerate the development of COYA 302, Coya’s lead therapeutic candidate, is being evaluated in multiple neurodegenerative diseases, including FTD.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : COYA 302,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Coya Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CST-3056,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : CuraSen Therapeutics

                            Deal Size : $5.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advanc...

                            Details : The funding will be used to to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease, from preclinical development to completion of Phase 1 studies.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 10, 2023

                            Lead Product(s) : CST-3056,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : CuraSen Therapeutics

                            Deal Size : $5.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Alzheimers Drug Discovery Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Astrocyte Pharmaceuticals

                            Deal Size : $6.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to E...

                            Details : The funding will accelerate the development of AST-004, a small molecule adenosine A3/A1 receptor agonist, aimed at treating acute brain injuries including stroke and traumatic brain injury (TBI), and further assess its potential in preclinical models of...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 18, 2023

                            Lead Product(s) : AST-004,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Astrocyte Pharmaceuticals

                            Deal Size : $6.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth